Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Sutro Biopharma's Short term Debt history spans 6 years, with the latest figure at $4.1 million for Q4 2023.

  • For Q4 2023, Short term Debt fell 67.51% year-over-year to $4.1 million; the TTM value through Dec 2023 reached $4.1 million, down 67.51%, while the annual FY2023 figure was $4.1 million, 67.51% down from the prior year.
  • Short term Debt for Q4 2023 was $4.1 million at Sutro Biopharma, down from $7.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $13.2 million in Q1 2023 and bottomed at $1.0 million in Q4 2019.
  • The 4-year median for Short term Debt is $7.1 million (2023), against an average of $8.1 million.
  • The largest annual shift saw Short term Debt crashed 78.83% in 2019 before it surged 300.0% in 2022.
  • A 4-year view of Short term Debt shows it stood at $1.0 million in 2019, then surged by 837.5% to $9.4 million in 2021, then soared by 33.33% to $12.5 million in 2022, then plummeted by 67.51% to $4.1 million in 2023.
  • Per Business Quant, the three most recent readings for STRO's Short term Debt are $4.1 million (Q4 2023), $7.1 million (Q3 2023), and $10.2 million (Q2 2023).